청소년 황반변성(JMD) 출시 및 파이프라인 약제 평가, 임상시험, 경쟁 구도

Juvenile Macular Degeneration (JMD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

US $ 3,495 ￦ 4,922,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,990 ￦ 9,845,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,485 ￦ 14,768,000

PDF (Global License)

PDF 보고서를 동일 기업(해외)의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다

한글목차

대상 16개국의 2023년 청소년 황반변성(JMD) 진단 이환 건수는 555,110예 이상으로 예측됩니다. JMD 치료 영역에서는 시판되고 있는 치료제가 부족하므로 미충족 임상 요구가 상당합니다. JMD 영역의 연구개발 활동은 매우 한정되어 있으며, 개발 중기부터 후기 단계에 있는 파이프라인 의약품은 6품목에 불과합니다. JMD의 임상시험 활동은 과거 10년간 매우 한정되어 있으며, 전체 26건의 시험에 불과합니다.

청소년 황반변성(JMD) 치료제의 현재 및 향후 경쟁 구도에 대해 데이터에 기반한 개요를 제공하고 있습니다.

목차

제1장 서문

제2장 주요 조사 결과

제3장 질병 상황

• 질병의 개요
• 역학의 개요
• 치료의 개요

제4장 시판약 평가

제5장 가격결정과 상환 평가

제6장 파이프라인 의약품 평가

• 제III상 파이프라인 의약품
• 개발 단계별 개요
• 분자 유형별 개요
• 작용기서별 개요
• 투여 경로별 개요
• 의약품 특이적 상전이 성공률(PTSR)과 승인의 가능성(LoA)
• 치료 영역 및 적응증 고유 PTSR 및 LoA

제7장 임상시험 평가

• 역사적 개요
• 단계별 개요
• 현황별 개요
• 진행중 및 계획중dls 시험 단계별 개요
• 가상 컴포넌트를 사용한 트라이얼
• 지역적 개요
• 지역별 단일국 및 다국적 시험
• 상위 20 스폰서와 단계별 내역
• 상위 20 스폰서의 현황별 내역
• 엔드포인트 현황별 개요
• 인종 및 민족별 개요
• 등록 데이터
• 임상시험 사이트 상위 20개국
• 세계의 TOP 20 사이트
• 실현 가능성 분석 - 지역적 개요
• 실현 가능성 분석 - 벤치마크 모델

제8장 거래 상황

• 지역별 합병, 인수, 전략적 제휴
• 최근 합병, 인수, 전략적 제휴

제9장 상업적 평가

• 주요 시장 참여 기업

제10장 향후 시장 촉진요인

제11장 부록

KSA

영문 목차

영문목차

Abstract

This reports provides a data-driven overview of the current and future competitive landscape in JMD therapeutics.

• More than 555,110 diagnosed prevalent cases of JMD are anticipated in 2023 in the 16 countries covered in GlobalData's epidemiology forecast for JMD.
• There are significant unmet clinical need in the JMD treatment space due to a lack of marketed therapies.
• R&D activity in the JMD space is very limited, with only six pipeline drugs in the mid-to-late-stage of development.
• Clinical trial activity in JMD has been very limited during the past 10 years, with only 26 trials conducted overall.

Scope

GlobalData's Juvenile Macular Degeneration (JMD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the JMD market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global JMD market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

5 Pricing and Reimbursement Assessment

6 Pipeline Drugs Assessment

• 6.1 Phase III Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Molecule Type
• 6.4 Overview by Mechanism of Action
• 6.5 Overview by Route of Administration
• 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.7 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Geographic Overview
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer

관련자료